Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.
Download (PDF, 272.9KB) -
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement.
-
Statement: Zantac (ranitidine) litigation – Delaware State Court Daubert Ruling
GSK disagrees with ruling by the Delaware State Court and will immediately seek an appeal.
-
New data at ASCO showcases the transformational potential of GSK's oncology portfolio
Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials.
Download (PDF, 374.8KB) -
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases
Jury in Valadez case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
-
FDA approves Benlysta (belimumab) Autoinjector for children with systemic lupus erythematosus
FDA approves GSK's 200mg subcutaneous Benlysta for patients five years of age or older. A treatment to inhibit B-lymphocyte stimulator.
Download (PDF, 100.1KB) -
US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab-gxly) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Application supported by statistically significant and clinically meaningful progression-free and overall survival data from RUBY trial
Download (PDF, 189.3KB) -
New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination
Download (PDF, 192.8KB) -
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Submission based on results from pivotal phase III trial showing all primary endpoints met
Download (PDF, 186.4KB) -
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Healthcare announces U.S. FDA approval of Dovato for the treatment of HIV-1 infection in adolescents 12 years of age and older.
Download (PDF, 236.4KB) -
GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers
GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S.
-
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in overall population.
Download (PDF, 250.5KB) -
GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise
We are committing up to $2 million in 2024 to support adult immunization and health equity programs.
Download (PDF, 158.4KB) -
ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
The data were presented by the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections network at CROI.
Download (PDF, 160.0KB) -
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
GSK announced the company’s first step towards delivering ultra long-acting injectable HIV treatment.
Download (PDF, 136.6KB) -
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
Key abstracts to be presented at CROI 2024 by ViiV Healthcare and its study partners.
Download (PDF, 350.9KB) -
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges
Full data set to be presented at an upcoming scientific conference.
Download (PDF, 161.5KB) -
GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)
Download (PDF, 189.2KB) -
GSK’s RSV vaccine, AREXVY, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk
GSK's RSV vaccine for at-risk adults aged 50-59 is under FDA review.
Download (PDF, 142.0KB) -
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
GSK announced that ViiV Healthcare, in collaboration with Pfizer and Shionogi, has recently launched Dovato in a blister pack in the U.S.
Download (PDF, 150.9KB)
